Physiological importance of dehydroepiandrosterone

The physiological function of dehydroepiandrosterone (DHEA) remains uncertain despite its high plasma concentration. Prior research has shown that DHEA circulates in large amounts, often as DHEAS, but its biological role is not fully understood. It was already known that DHEA can be metabolized into various androgens and estrogens. However, no prior work had resolved how DHEA's effects vary with hormonal context. This gap motivated an investigation into whether DHEA acts as an estrogen or androgen depending on the surrounding hormone levels. The uncertainty around DHEA's function in obesity and insulin resistance also drove this study. The lack of clarity on DHEA's role in breast cancer cell growth in different estrogen environments was another key question. This uncertainty created a need to explore DHEA's dual potential as both an estrogen and androgen antagonist.

The aim of this work is to clarify how DHEA functions in different hormonal environments. The specific problem involves understanding whether DHEA behaves as an estrogen or androgen depending on surrounding hormone levels. This study addresses the unresolved question of DHEA's physiological role in premenopausal and postmenopausal women. It also seeks to determine how DHEA affects cardiovascular disease risk in men and women. The motivation stems from the lack of consensus on DHEA's effects in obesity and insulin resistance. The study also targets the unclear mechanism of DHEA's influence on breast cancer cell growth. By examining DHEA's interactions with estrogen receptors and androgen pathways, the work aims to provide a clearer framework for its physiological function.

The study analyzed DHEA's metabolism and receptor interactions in different hormonal conditions. Researchers examined DHEA's conversion to ADIOL and its competitive binding to estrogen receptors. They also assessed DHEA's metabolism to androstenedione and testosterone in women. The team evaluated DHEA's role in abdominal obesity and insulin resistance in premenopausal and postmenopausal states. They tested DHEA's effects on breast cancer cell lines under low and high estrogen conditions. The study compared DHEA's protective role in men's cardiovascular disease with its effects in women. Researchers used in vitro experiments to observe tumor growth responses to DHEA. The approach combined biochemical assays with clinical observations to determine DHEA's physiological behavior.

DHEA's effects depend on the hormonal environment, showing either estrogen-like or androgen-like properties. In premenopausal women, DHEA may act as an estrogen antagonist through ADIOL binding to estrogen receptors. Alternatively, it may function as an androgen by converting to testosterone. DHEA contributes to abdominal obesity and insulin resistance in women. In postmenopausal women, DHEA metabolism to testosterone may increase cardiovascular disease risk. However, the decline in DHEA with age and ADIOL's estrogen-like effects may counterbalance this risk. In breast cancer cell lines, DHEA stimulates tumor growth in low estrogen conditions but inhibits growth in high estrogen environments. In men, DHEA's estrogen-like effects appear to protect against cardiovascular disease.

The authors suggest that DHEA's physiological role is context-dependent, varying with the hormonal milieu. DHEA may act as an estrogen antagonist in premenopausal women through ADIOL's competitive binding. It may also function as an androgen by converting to testosterone. DHEA's contribution to abdominal obesity and insulin resistance is highlighted. Postmenopausal women may face increased cardiovascular disease risk due to DHEA's conversion to testosterone. However, aging-related DHEA decline and ADIOL's estrogen-like effects may reduce this risk. In breast cancer cells, DHEA's effect on tumor growth depends on estrogen levels. In men, DHEA's estrogen-like properties may offer cardiovascular protection.